Skip to main content

Remote Job Finders (RJF)

Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck

Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s ‘disease agnostic’ pipeline and approach to business development.

Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.
Scroll to top